General Surgical Innovations
This article was originally published in The Gray Sheet
Manufacturer of tissue dissection systems for minimally invasive surgery reports Aug. 4 that it will be allowed to recover legal fees in connection with a patent infringement suit filed by Guidant subsidiary Origin Medsystems in San Jose, California federal court. Earlier, the court found that Origin had obtained the patent through misrepresentations, according to GSI. For the fourth quarter ended June 30, GSI reported revenues of $1.3 mil., down from $2.5 mil. in the fourth quarter of fiscal 1997, and a net loss of $3 mil. versus $971,000 a year ago. For the 12 months, revenues advanced 24% to $5.2 mil., and the company's net loss increased to $9.1 mil. from $1.9 mil. in 1997
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.